# CLN-049 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/cln-049

> CLN-049, sponsored by Cullinan Therapeutics, Inc. (CGEM): 3 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | CLN-049 |
| Codes | CLN-049 |
| Sponsor | Cullinan Therapeutics, Inc. (CGEM) https://sec-api.dev/companies/cgem/catalysts |
| Indications | previously untreated aml, relapsed/refractory aml, newly diagnosed aml, aml and measurable residual disease |
| Modality |  |
| FDA designations | fast track, orphan |

## Timeline

### Dec 2023: trial start

- Status: completed. Date confidence: month. Stage: 1. Indication: AML and measurable residual disease.
- First seen 2025-02-27, last confirmed 2026-03-10.
- SEC Form 10-K (accession 0001193125-26-099362): "In December 2023, we initiated the ongoing Phase 1 clinical trial designed to evaluate the safety and preliminary efficacy of CLN-049 in patients with AML and measurable residual disease following induction therapy." https://www.sec.gov/Archives/edgar/data/1789972/000119312526099362/cgem-20251231.htm
- SEC Form 10-K (accession 0000950170-25-028346): "In December 2023, we initiated the ongoing Phase 1 clinical trial designed to evaluate the safety and preliminary efficacy of CLN-049 in measurable residual disease-positive AML." https://www.sec.gov/Archives/edgar/data/1789972/000095017025028346/cgem-20241231.htm

### Oct 2026: trial start

- Status: completed. Date confidence: month. Stage: 2. Indication: relapsed/refractory AML.
- First seen 2026-11-10, last confirmed 2026-11-10.
- SEC Form 10-Q (accession 0001193125-26-454417): "In October 2026, we initiated a potentially registrational Phase 2 clinical trial in patients with relapsed/refractory AML." https://www.sec.gov/Archives/edgar/data/1789972/000119312526454417/cgem-20260930.htm

### Q4 2026: trial start

- Status: scheduled. Date confidence: quarter. Stage: 1/2. Indication: previously untreated AML.
- First seen 2026-03-10, last confirmed 2026-08-06.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-336700): "In Q4 2026, the Company will initiate a Phase 1/2 study evaluating the combination of CLN-049, venetoclax, and azacitidine in patients with previously untreated AML." https://www.sec.gov/Archives/edgar/data/1789972/000119312526336700/cgem-ex99_1.htm
- SEC Form 10-Q (accession 0001193125-26-336717): "In the fourth quarter of 2026, we also will initiate a Phase 1/2 clinical trial evaluating the combination of CLN-049, venetoclax, and azacitidine as a potential frontline treatment for patients with previously untreated AML." https://www.sec.gov/Archives/edgar/data/1789972/000119312526336717/cgem-20260630.htm
- SEC Form 10-K (accession 0001193125-26-099362): "In the fourth quarter of 2026, we plan to initiate a Phase 1/2 clinical trial evaluating CLN-049 as a potential frontline treatment in combination with current standard-of-care treatment for patients with newly diagnosed AML." https://www.sec.gov/Archives/edgar/data/1789972/000119312526099362/cgem-20251231.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/cln-049.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "CLN-049 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/cln-049

```bibtex
@misc{secapidev_pdufa_cln_049_20261116,
  title        = {CLN-049 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/cln-049}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_cln_049_20261116","title":"CLN-049 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/cln-049","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
